{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000116","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.672181+00:00","generated_at":"2026-05-28T06:55:17.987186+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Compass Therapeutics provides pipeline update; cash at $127M, tovecimig data Q1 2025","bullets":["Estimated $127M cash at YE 2024; cash runway expected into Q1 2027.","Top-line Phase 2/3 data for tovecimig (CTX-009) in BTC expected end of Q1 2025.","New drug candidate CTX-10726 (PD-1 x VEGF-A bispecific) advancing; IND submission targeted by YE 2025.","Third dosing cohort fully enrolled for CTX-8371 Phase 1; preliminary data H2 2025.","Two Phase 2 biomarker trials planned for mid-2025: tovecimig in DLL4+ CRC and CTX-471 in NCAM/CD56+ tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000116","json":"https://secwatch.observer/filing/0001171843-25-000116.json","markdown":"https://secwatch.observer/filing/0001171843-25-000116.md","text":"https://secwatch.observer/filing/0001171843-25-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/0001171843-25-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000116/f8k_010725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:55:17.987186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}